US FDA oncology drug approvals in 2014

被引:5
作者
Wolford, Juliet E. [1 ]
Tewari, Krishnansu S. [1 ]
机构
[1] Univ Calif Irvine, Med Ctr, Chao Family NCI Designated Comprehens Canc Ctr, Orange, CA 92868 USA
关键词
accelerated approval; cancer drugs; orphan drug designation; priority review; US FDA; regulatory approval; OLAPARIB MAINTENANCE THERAPY; OVARIAN-CANCER; DOUBLE-BLIND; MULTICENTER; BEVACIZUMAB; IPILIMUMAB; NIVOLUMAB; IBRUTINIB; MELANOMA;
D O I
10.2217/FON.15.106
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancer is a close second to heart disease for cause of death in the USA, and could soon surpass heart disease as the population ages and the incidence of cancer continues to increase. While heart disease can be addressed through behavior modification and education (e. g., smoking cessation, dietary changes, exercises that promote cardiovascular fitness), pharmacology and improved surgical devices and methods, cancer ultimately requires improved and novel drug treatments to bring mortality rates down. In 2014, the US FDA approved 17 drugs and/or drug combinations in 12 disease sites for a total of 19 indications in melanoma, hematologic malignancies, gastrointestinal carcinoma, non-small-cell lung cancer, gynecologic malignancies and lymphoma/lymphoproliferative disorders.
引用
收藏
页码:1931 / 1945
页数:15
相关论文
共 35 条
[1]  
[Anonymous], CANC BEATS ALL OTHER
[2]  
[Anonymous], ESMO 2014 C MADR SPA
[3]  
[Anonymous], CLIN CANC ADV 2013 F
[4]  
[Anonymous], ANN M AM SOC HEM NEW
[5]   Oncology's trials [J].
Booth, B ;
Glassman, R ;
Ma, P .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (08) :609-610
[6]   Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia [J].
Byrd, J. C. ;
Brown, J. R. ;
O'Brien, S. ;
Barrientos, J. C. ;
Kay, N. E. ;
Reddy, N. M. ;
Coutre, S. ;
Tam, C. S. ;
Mulligan, S. P. ;
Jaeger, U. ;
Devereux, S. ;
Barr, P. M. ;
Furman, R. R. ;
Kipps, T. J. ;
Cymbalista, F. ;
Pocock, C. ;
Thornton, P. ;
Caligaris-Cappio, F. ;
Robak, T. ;
Delgado, J. ;
Schuster, S. J. ;
Montillo, M. ;
Schuh, A. ;
de Vos, S. ;
Gill, D. ;
Bloor, A. ;
Dearden, C. ;
Moreno, C. ;
Jones, J. J. ;
Chu, A. D. ;
Fardis, M. ;
McGreivy, J. ;
Clow, F. ;
James, D. F. ;
Hillmen, P. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (03) :213-223
[7]   Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia [J].
Byrd, John C. ;
Furman, Richard R. ;
Coutre, Steven E. ;
Flinn, Ian W. ;
Burger, Jan A. ;
Blum, Kristie A. ;
Grant, Barbara ;
Sharman, Jeff P. ;
Coleman, Morton ;
Wierda, William G. ;
Jones, Jeffrey A. ;
Zhao, Weiqiang ;
Heerema, Nyla A. ;
Johnson, Amy J. ;
Sukbuntherng, Juthamas ;
Chang, Betty Y. ;
Clow, Fong ;
Hedrick, Eric ;
Buggy, Joseph J. ;
James, Danelle F. ;
O'Brien, Susan .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (01) :32-42
[8]  
Caplin ME, 2014, NEW ENGL J MED, V371, P1556, DOI [10.1056/NEJMoa1316158, 10.1056/NEJMc1409757]
[9]   Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations [J].
Flaherty, Keith T. ;
Infante, Jeffery R. ;
Daud, Adil ;
Gonzalez, Rene ;
Kefford, Richard F. ;
Sosman, Jeffrey ;
Hamid, Omid ;
Schuchter, Lynn ;
Cebon, Jonathan ;
Ibrahim, Nageatte ;
Kudchadkar, Ragini ;
Burris, Howard A., III ;
Falchook, Gerald ;
Algazi, Alain ;
Lewis, Karl ;
Long, Georgina V. ;
Puzanov, Igor ;
Lebowitz, Peter ;
Singh, Ajay ;
Little, Shonda ;
Sun, Peng ;
Allred, Alicia ;
Ouellet, Daniele ;
Kim, Kevin B. ;
Patel, Kiran ;
Weber, Jeffrey .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (18) :1694-1703
[10]   Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial [J].
Fuchs, Charles S. ;
Tomasek, Jiri ;
Yong, Cho Jae ;
Dumitru, Filip ;
Passalacqua, Rodolfo ;
Goswami, Chanchal ;
Safran, Howard ;
dos Santos, Lucas Vieira ;
Aprile, Giuseppe ;
Ferry, David R. ;
Melichar, Bohuslav ;
Tehfe, Mustapha ;
Topuzov, Eldar ;
Zalcberg, John Raymond ;
Chau, Ian ;
Campbell, William ;
Sivanandan, Choondal ;
Pikiel, Joanna ;
Koshiji, Minori ;
Hsu, Yanzhi ;
Liepa, Astra M. ;
Gao, Ling ;
Schwartz, Jonathan D. ;
Tabernero, Josep .
LANCET, 2014, 383 (9911) :31-39